Stocks › Cancer Research › BMY

Bristol-Myers Squibb BMY

US equityMarket cap rank #158Cancer Research

$62.14 +$0.00 (0.00%)

Market closed · Nov 9, 10:50 pm ET · Last extended-hours $62.43 +0.47%

Open$62.88

Prev close$62.14

Day range$61.80 – $63.06

Volume7.67M

Market cap$127.02B

P/E (TTM)13.8

Dividend yield4.06%

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership82.5%-0.62 pts vs. prior quarter

Institutions holding2,960+46 vs. prior quarter

Insider trades (recent)36 buys / 14 sellsNet buying

Short interest2.45% of floatDays to cover 3.7 · as of 15 Oct 2026

Short-sale volume share17.3%5-day average of daily volume

Short-sale volume as % of daily volume

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: −$17.51M (12 inflow days, 8 outflow days).

Net flow by order size, last 20 sessions

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 27.1% of shares outstanding.

Largest holders

BlackRock8.82%
Vanguard Capital Management, LLC7.08%
State Street Global Advisors5.01%
Charles Schwab Investment Management3.31%
J.P. Morgan Asset Management, Inc.2.89%
Geode Capital Management, LLC2.48%
Vanguard Portfolio Management, LLC2.29%
Norges Bank Investment Management1.80%

By investor type

Mutual Fund67.95%
Public Company3.89%
Hedge Fund2.87%
Government Pension Fund2.61%
Private Company2.11%
Sovereign Wealth Fund1.90%
Insurance Company0.32%
Family Office/Trust0.30%

Reported short interest has fallen from 2.56% to 2.45% of float over the last 6 biweekly reports (31 Jul 2026 to 15 Oct 2026).

Recent institutional activity

Holder	Type	Period	Share change	New stake
Deka Investment GmbH	Mutual Fund	2026/Q3	+2,080,465	0.3%
T. Rowe Price Group, Inc.	Mutual Fund	2026/Q3	+21,462,628	1.6%
BlackRock	Mutual Fund	2026/Q3	+8,702,106	8.8%
Charles Schwab Investment Management	Mutual Fund	2026/Q3	+6,480,204	3.3%
Nordea Investment Management AB	Mutual Fund	2026/Q3	+6,019,226	0.4%
FMR	Mutual Fund	2026/Q3	+4,537,393	0.5%
State Street Global Advisors	Mutual Fund	2026/Q3	+3,844,026	5.0%
Allianz Asset Management AG	Mutual Fund	2026/Q3	+3,088,953	0.2%
The Goldman Sachs Group, Inc.	Public Company	2026/Q3	+2,752,724	0.3%
La Caisse de dépôt et placement du Québec	Government Pension Fund	2026/Q3	+2,744,671	0.2%
UBS Asset Management	Mutual Fund	2026/Q3	+1,795,680	1.6%
Pacific Investment Management Company LLC	Mutual Fund	2026/Q3	+1,395,538	0.3%
Geode Capital Management, LLC	Mutual Fund	2026/Q3	+1,156,903	2.8%
Employees Provident Fund	Government Pension Fund	2026/Q3	+1,131,333	0.2%
Amundi Asset Management	Mutual Fund	2026/Q3	+1,115,019	0.4%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

Date	Insider	Title	Transaction	Shares	Price	Held after
1 Oct 2026	Cari Gallman	Executive VP, General Counsel & Chief Policy Officer	Derivative Exercise and Sale	-2,332	$61.15	15,876
1 Oct 2026	Cari Gallman	Executive VP, General Counsel & Chief Policy Officer	Derivative Exercise and Retained	+2,227	–	15,876
29 Sep 2026	Derica Rice	Independent Director	Other Derivative Acquisition	+620	–	42,085
29 Sep 2026	Phyllis Yale	Independent Director	Other Derivative Acquisition	+560	–	45,980
29 Sep 2026	Peter Arduini	Independent Director	Other Derivative Acquisition	+560	–	74,077
29 Sep 2026	Theodore Samuels	Lead Independent Director	Other Derivative Acquisition	+821	–	71,859
29 Sep 2026	Michael McMullen	Independent director	Other Derivative Acquisition	+560	–	17,051
8 Sep 2026	Cristian Massacesi	Executive VP, Chief Medical Officer & Head of Development	Open Market Disposition	-6,249	$64.57	18,748
31 Aug 2026	Wendy Bartie	Executive VP & Chief Corporate Affairs Officer	Derivative Exercise and Sale	-633	$66.92	12,684
31 Aug 2026	Wendy Bartie	Executive VP & Chief Corporate Affairs Officer	Derivative Exercise and Retained	+603	$66.92	12,684
24 Aug 2026	Phil Holzer	Senior Vice President	Open Market Disposition	-500	$67.50	16,862
31 Jul 2026	Cristian Massacesi	Executive VP, Chief Medical Officer & Head of Development	Derivative Exercise and Sale	-26,175	$65.31	24,997
31 Jul 2026	Cristian Massacesi	Executive VP, Chief Medical Officer & Head of Development	Derivative Exercise and Retained	+24,997	–	24,997
31 Jul 2026	Cari Gallman	Executive VP, General Counsel & Chief Policy Officer	Derivative Exercise and Sale	-543	$65.31	13,649
31 Jul 2026	Cari Gallman	Executive VP, General Counsel & Chief Policy Officer	Derivative Exercise and Retained	+518	–	13,649
29 Jun 2026	Derica Rice	Independent Director	Other Derivative Acquisition	+672	–	41,069
29 Jun 2026	Phyllis Yale	Independent Director	Other Derivative Acquisition	+607	–	44,986
29 Jun 2026	Peter Arduini	Independent Director	Other Derivative Acquisition	+607	–	72,816
29 Jun 2026	Theodore Samuels	Lead Independent Director	Other Derivative Acquisition	+889	–	70,361
29 Jun 2026	Michael McMullen	Independent director	Other Derivative Acquisition	+607	–	16,333

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report date	Shares short	% of float	Days to cover
15 Oct 2026	49,948,083	2.4%	3.7
30 Sep 2026	45,847,626	2.2%	3.0
15 Sep 2026	41,969,577	2.1%	5.8
31 Aug 2026	44,073,318	2.2%	5.3
14 Aug 2026	45,852,662	2.2%	3.5
31 Jul 2026	52,336,079	2.6%	4.6

Discussion

No comments yet — be the first to weigh in on BMY.